semaglutide approved Novo Nordisk's weight-loss pill wins FDA approval European Commission Approves 7.2 mg
Description
Novo Nordisk chose to continue using semaglutide, the same active ingredient found in Wegovy and Ozempic injections
No placebo-treated patients reported suicidal behavior or ideation
If you have medical concerns or questions, discuss with your health care professional
2004;53(Suppl 3):S16S21
The SURMOUNT trials measured outcomes at 72 weeks, showing substantial weight loss that continued throughout the treatment period
